PCV13 Program Implementation National Immunization Conference Atlanta, Georgia April 21, 2010 Andrew Kroger, MD Abigail Shefer, MD Associate Director for.

Slides:



Advertisements
Similar presentations
Tennessee VFC Highlights and Updates Robert H. Brown
Advertisements

North Carolina Immunization Program (NCIP) Overview
CDC Director’s Perspective Immunization Program Managers Meeting Thomas R. Frieden, MD, MPH Director, CDC Administrator, ATSDR.
1 1 Immunization Update 2011 Connecticut Immunization Teleconference April 19, 2011 William Atkinson, MD, MPH National Center for Immunization and Respiratory.
INCREASING UPTAKE OF ADOLESCENT VACCINES IN NC SCHOOL HEALTH CENTERS Ashley Leighton, MPH Cervical Cancer-Free NC Cathy DeMason, RN, BSN Director, Rockingham.
Public Health Service Response to Influenza Vaccine Supply Problems Lance E. Rodewald, MD Immunization Services Division National Immunization Program.
Economic Evaluation of Routine Childhood Immunization with DTaP, Hib, IPV, MMR and HepB Vaccines in the United States, 2001 Fangjun Zhou Health Services.
Implementing New Vaccines and Vaccine Recommendations National Vaccine Advisory Committee Washington, DC September 26, 2006 Lance E. Rodewald, MD Director,
Vaccine Supply Update Jeanne M. Santoli Vaccine Supply and Assurance Branch January 22, 2010.
Influenza Vaccination Update for Jeanne M. Santoli, MD, MPH Deputy Director, Immunization Services Division National Center for Immunization and.
Plenary #2 -- Grow Promoting Registry Growth through Programmatic Collaboration and Data Quality Improvement Initiatives Plenary #2 -- Grow Promoting Registry.
NCIP Borrowing & Replacing Policy and the November 9, 2011.
A Vaccine Supply Update For The U.S. Market A Presentation At The National Vaccine Advisory Committee Meeting June 3, 2003 Dean Mason Chief, Program Support.
A Vaccine Supply Update For The U.S. Market A Presentation At National Advisory Committee Meeting February 4, 2003 Dean Mason Chief, Program Support Branch.
Adult Immunization: Goals, Challenges, and a role for the National Vaccine Advisory Committee October 22, 2007 Raymond A. Strikas, MD National Vaccine.
Vaccination Strategies Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases Centers for.
Progress in adolescent vaccination coverage levels in the United States National Immunization Conference Washington, DC March 31, 2011 Shannon Stokley,
1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.
Using Medical Claims Data for Timely Estimation of Rotavirus Vaccine Coverage Lone Simonsen, George Washington University and SDI Farid Khan and Laurel.
Successful Strategies that Prevent Vaccine Wastage Cherry Boardman, R.N., M.S.N. Becky Burkhart, M.Ed. Kathy Fredrickson, M.S., M.P.H. Arizona Immunization.
Department of Child Support Services OFFICE OF AUDITS AND COMPLIANCE.
Implementation of an Elementary School-located Influenza Vaccination Program with Billing of Third-Party Payers 44 th National Immunization Conference.
Evaluation of the 2004 pneumococcal conjugate vaccine shortage utilizing data from the Michigan Childhood Immunization Registry Norma Allred, PhD, John.
2007 National Health Policy Conference Preparing to Protect: Flu Vaccines from Production to Consumption A Public Health Perspective Daniel Hopfensperger.
Kindergarten Considerations and Timeline to Incorporate a New Vaccine in City and State Immunization Programs in the United States Katelyn Wells MS, Association.
University of Michigan Health System Primary Care Providers’ Perspectives on a Registry-Based Indicator to Identify High-Risk Children for Influenza Vaccination.
Using Best Practice Recommendations to Improve Data Quality Assurance in an IIS. Nichole D. Lambrecht, MSc; Mike McPherson; Sue Bowden, Kristin Shore,
How can information systems help us?
CO Immunization Program VTrckS Pilot Experience Joni Reynolds, Program Director.
C ALIFORNIA D EPARTMENT OF P UBLIC H EALTH, I MMUNIZATION B RANCH 07/20161 C ONDITIONAL A DMISSIONS.
Vaccines for Children Program Incident Follow-up Protocol Betsy Hubbard MN, RN Darren Robertson Krista Rietberg, MPH David Bibus, MPH Lauren Greenfield.
What’s Up With All Those Other Vaccines?
Learning Collaborative #5 September 2016
Some Perspectives on Vaccination of Adults
Analysis of VFC Provider Quality Assurance Survey Data
Georgia Immunization Rates
Module 5 Recording and monitoring uptake of rotavirus vaccine
Epidemiology Section APHA Tuesday, Nov. 6, 2007
Emerging Gaps in Financing for New Vaccines
VFC Site Visit Questionnaire and AFIX as Tools for Quality Assessment
Vaccination Strategies
Recommended Timeline for Influenza Vaccinations
Evidence-Based Strategies to Increase Adult Vaccination Rates Recommendations of the Task Force on Community Preventive Services Megan C. Lindley, MPH.
Texas Department of State Health Services Dr
2010 Tennessee Immunization Requirements for School Entrance:
Implementation Issues for HPV Vaccine
Improving HPV rates at the clinic level
Increasing Capacity to Provide Immunization Services
Recording and monitoring uptake of JE vaccine
Women’s Health Care and Education Coalition
Recording and monitoring uptake of fractional IPV (fIPV)
Chicago Department of Public Health
What’s New with VFC? A Lot
Physician Adoption of Adolescent Tdap Recommendations
Strategies for Private Provider Participation in Registries
Discussion Topics Addressing Immunization Challenges
Dose by Dose Accountability and CAIR
Merced County Immunization Program Immunization Rates Best Practices
Module 5 Recording and monitoring uptake of rotavirus vaccine
Module 5 Recording and monitoring uptake of rotavirus vaccine
Module 5 Recording and monitoring uptake of rotavirus vaccine
National Immunization Conference
Updating the National Vaccine Plan: A roadmap for the next decade A National, not Federal, Plan December 11, 2009.
Indiana State Department of Health
Immunization in the Era of Health Reform: What’s Next?
Assessing the number of antigens received per visit and frequency of vaccination visits among children months of age, IIS sentinel sites,
Kimberly Ralston, MPH, Jennifer Sterling, Kathryn McAuliffe, MPH,
Karen A. Cullen, Diana L. Bartlett, C. Robinette Curtis
Influenza Vaccine Delay From the Primary Care Physician’s Perspective
March 8, 2006 New ACIP Hepatitis B Recommendations
Presentation transcript:

PCV13 Program Implementation National Immunization Conference Atlanta, Georgia April 21, 2010 Andrew Kroger, MD Abigail Shefer, MD Associate Director for Science, ISD

Outline  Implementation  Challenges  Communication and educational materials  Monitoring uptake and evaluation activities

ImplementationImplementation

Implementation  Inventory management  Licensure and recommendations  Logistics of implementation

Inventory management  Worked with state immunization programs to prepare for PCV13 transition – Inventory of PCV7 brought down to ~3 weeks in state McKesson depots – Effort to minimize wastage of PCV7  Letter to Grantees – Dec 2009 and Jan 2010 – Place smaller more frequent orders – Communicate with providers

Schedule of events  Feb 24 - PCV13 licensed (same day as ACIP meeting)  Feb 24 – ACIP meeting and vote to recommend PV13  March 3 – Posting of provisional recs  March 12 – ACIP recs published in MMWR

The purpose of this resolution is to reflect the replacement of the seven valent pneumococcal conjugate vaccine (PCV7) with the thirteen valent conjugate vaccine (PCV13). Note: Until the transition between seven valent pneumococcal conjugate vaccine (PCV7) and thirteen valent pneumococcal conjugate vaccine (PCV13) is complete and providers have sufficient supplies of thirteen valent pneumococcal conjugate vaccine in their offices to meet demand among VFC eligible children, the VFC program will continue to include seven valent pneumococcal conjugate vaccine and the schedule provided in VFC resolution 2/09-1 should be followed for administration of PCV7 during that time. VFC resolution 2/09-1 is repealed and replaced by the following: The purpose of this resolution is to reflect the replacement of the seven valent pneumococcal conjugate vaccine (PCV7) with the thirteen valent conjugate vaccine (PCV13). Note: Until the transition between seven valent pneumococcal conjugate vaccine (PCV7) and thirteen valent pneumococcal conjugate vaccine (PCV13) is complete and providers have sufficient supplies of thirteen valent pneumococcal conjugate vaccine in their offices to meet demand among VFC eligible children, the VFC program will continue to include seven valent pneumococcal conjugate vaccine and the schedule provided in VFC resolution 2/09-1 should be followed for administration of PCV7 during that time. VFC resolution 2/09-1 is repealed and replaced by the following: VFC Resolution

Vaccine distribution and use  Private – orders started being shipped 3/15 – Pfizer accepting returns for PCV7, even for partial returns  Public – contract negotiations completed within 2 weeks and available for ordering 3/18 – McKesson inventory – swap out PCV13 for PCV7 and pay difference – Providers should contact their state immunization programs for guidance on returns of PCV7 vaccine purchased with public funds – In order to receive credit, all unused PCV7 must be returned to McKesson by May 10  CDC policy on two directional borrowing between VFC and private stock vaccine

Can a provider borrow between private stock and VFC stock of PCV13? *  According to CDC’s policy on two directional borrowing between VFC and private stock vaccine, CDC allows borrowing of VFC vaccine to be administered to non-VFC eligible patients in limited circumstances due to an unexpected lack of private stock vaccine. Providers are required to document these situations and also situations when it is necessary to borrow from private stock due to lack of VFC vaccine. The practice is not allowed in all states and providers should check with their state immunization or VFC program office * Guidance sent out to Grantees Oct 2009 and posted on VFC website

Highlights of implementation recommendations  PCV13 preferred if both available in provider office  Don’t discard your PCV7 doses until supplies are fully transitioned  Give PCV7 if that is only pneumococcal conjugate vaccine in office and child is indicated  Supplemental dose should be given at next medical visit (no active recall)  Supplies of PCV13 should be adequate to allow providers to implement routine and supplemental doses

ChallengesChallenges

Challenges  Active recall not required but providers still need to identify children for supplemental doses of PCV13 during medical visits – Strategies to reduce missed opportunities may include provider reminders and flagging charts during office visits  Communicating with parents – Emphasizing that PCV13 provides ‘additional ‘ protection but that PCV7 was not an ineffective vaccine  Provider office with PCV13 in stock for private pay children before VFC doses available  Because of cost difference, anecdotal reports that private providers are keeping their PCV7 to use until supply gone before ordering PCV13

Communication and Educational Materials

Educational resources  Q & A for parents: April vac/pneumo/vac-faqs.htm vac/pneumo/vac-faqs.htm  Q & A for providers: April vac/pneumo/vac-PCV13-hcp-faqs.htm vac/pneumo/vac-PCV13-hcp-faqs.htm  Podcast – “New & Improved Vaccine” p?f= p?f=

Monitoring uptake and evaluation activities

Monitoring uptake  National Immunization survey – gold standard to monitor uptake of vaccines – ~23,000 households/year used in analyses – Jan PCV13 added to provider IHQ (Immunization History questionnaire) so able to identify PCV7 and PCV13 ; ability to capture up to 6 pneumococcal-containing doses (likely that high risk kids might get up to 6 doses) – Describe uptake by provider type, VFC status, income, etc…  Programmatic indicator of uptake – Number of doses PCV13 purchased off the CDC Federal contract – Baseline (Jan –March 2010 (Q2) – Monitor increase for Q4 (expect increase because of supplemental dose)

Evaluation Activities  Early uptake and transition to PCV13 – IIS analysis (Fall 2010)  Provider attitudes/practices, barriers – Survey (Fall 2010)  Vaccine Effectiveness – EIP sites (Spring 2011)

Evaluation Activities  Uptake and transition to PCV13 – CVX codes incorporated into IIS so that PCV13 can be distinguished from PCV7 – Sentinel IIS site analysis - Fall 2010  AZ, CO, MI, MN, ND, NYC, OR, WI  Earliest window into PCV13 uptake  Provider attitudes, practices, barriers – Sentinel physician (Peds/FP) and Program managers survey - Fall 2010 – Describe pattern of PCV7 and PCV13 administration by public/private, provider type, identify barriers and facilitators of transition

Links for CDC resources  vac/pneumo/default.htm vac/pneumo/default.htm vac/pneumo/default.htm  short-both.htm short-both.htm short-both.htm  faqs.htm faqs.htm faqs.htm  faqs.htm faqs.htm faqs.htm

Acknowledgements  PCV13 Vaccine Implementation WG – Jeanne Santoli – Pekka Nuorti – Matt Moore – Carolyn Grace Davis – Joyalyn Hill – Andrew Kroger – Bill Atkinson – Mary McCauley – Allison Patti